RecruitingNCT06438965

MSOT as Non-invasive Biomarker for Diagnosis and Monitoring of Neuromuscular Diseases

Multispectral Optoacoustic Imaging (MSOT) as Non-invasive Biomarker for Diagnosis and Monitoring of Neuromuscular Diseases (MSOT-NMD)

Sponsor

Children's Hospital of Eastern Ontario

Enrollment

240 participants

Start Date

Feb 7, 2025

Study Type

OBSERVATIONAL

Conditions

Neuromuscular Diseases

Summary

The goal of this study is to learn if Multispectral Optoacoustic Tomographs (MSOT) works to diagnose and follow the course of neuromuscular diseases (NMDs) in children. MSOT scans will be obtained from muscle region to measure hemo/myoglobin, collagen and lipid content/signal and oxygenation in patients with neuromuscular diseases. No additional research activities -other than MSOT - will be done during this study. Existing clinical, laboratory and imaging data from standard-of-care procedures will be correlated with the MSOT data. The expected total duration of the study is approximately 36 months. Repeated measurements will be done to evaluate disease progression and the value of MSOT in NMD.

Eligibility

Max Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a medical device called Multispectral Optoacoustic Tomography (MSOT) for people with neuromuscular diseases. The study is currently recruiting participants at 1 location. People eligible for this study include up to age 18 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEMultispectral Optoacoustic Tomography (MSOT)

MSOT scans will be obtained from two muscle region to measure hemo/myoglobin, collagen and lipid content/signal and oxygenation in patient with neuromuscular diseases.